Please assess the completion status of the following clinical trial:

Trial Title: TAK-438 - Safety, Blood Levels & Effects of Repeated Doses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects aged 18 to 45, inclusive, who are in good health, as determined by medical history, physical examination, clinical laboratory evaluations and urine drug screen.~* The subject has the ability to tolerate the pH probe for 24 hours prior to Randomization (Day 1).~Exclusion Criteria:~* Clinically significant history of hypersensitivity to any drug or food or any excipients of TAK-438~* History of gastroesophageal reflux disease (GERD), symptomatic GERD, erosive esophagitis, duodenal ulcer,gastric ulcer, dyspepsia, Barrett's esophagus, or Zollinger-Ellison syndrome~* The subject has a positive test result for Helicobacter pylori at the Initial Screening Visit~* Any clinically significant results from physical examinations or clinical laboratory results as deemed by the investigator.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1: TAK-438 10 mg (Type: EXPERIMENTAL): TAK-438 10 mg tablets, orally, once, daily, for 7 days.
- Cohort 2: TAK-438 20 mg (Type: EXPERIMENTAL): TAK-438 20 mg tablets, orally, once, daily, for 7 days.
- Cohort 3: TAK-438 40 mg (Type: EXPERIMENTAL): TAK-438 40 mg tablets, orally, once, daily, for 7 days.
- Cohort 4: TAK-438 30 mg (Type: EXPERIMENTAL): TAK-438 30 mg tablets, orally, once, daily, for 7 days.
- Cohorts 1-4: Placebo (Type: PLACEBO_COMPARATOR): TAK-438 placebo-matching tablets, orally, once, daily, for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).